Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis - PubMed (original) (raw)

Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis

K Nakanishi et al. J Exp Med. 1984.

Abstract

B cells cultured with anti-IgM, BSF-p1, and B15-TRF will differentiate into high rate IgM-synthesizing cells in the presence of supernatants from EL-4 cells that have been induced with phorbol myristate acetate. These supernatants contain two molecular species (EL-TRFs) that have differentiative activity. One co-migrates with interleukin 2 (IL-2) and its activity is blocked by antibody to the IL-2 receptor. Furthermore, molecularly cloned IL-2, at concentrations of 100 U/ml or more, expresses such EL-TRF activity. The EL-TRF activity of cloned IL-2 can also be inhibited by antibody to the IL-2 receptor. The other material with EL-TRF activity has a molecular weight of approximately 32,000. This material lacks IL-2 activity. Antibody to the IL-2 receptor does not impair its function. B cells stimulated with anti-IgM and BSF-p1, with or without B15-TRF, express determinants that react with two monoclonal antibodies which recognize distinct epitopes on the T cell IL-2 receptor. These determinants are present at much lower density (approximately 100-fold) on stimulated B cells that on HT-2 cells, an IL-2-dependent T cell line. Very small amounts of [3H]IL-2 (less than 1,000 molecules per cell) bind to activated B cells. These results indicate that IL-2 binds to a receptor on appropriately prepared B cells and causes them to differentiate into high rate IgM-synthesizing cells. The physiologic significance of the B cell differentiative activity of IL-2 remains to be investigated.

PubMed Disclaimer

Similar articles

• Soluble factors involved in B cell differentiation: identification of two distinct T cell-replacing factors (TRF).
  Nakanishi K, Howard M, Muraguchi A, Farrar J, Takatsu K, Hamaoka T, Paul WE. Nakanishi K, et al. J Immunol. 1983 May;130(5):2219-24. J Immunol. 1983. PMID: 6601148
• T cell replacing factor/interleukin 5 induces not only B-cell growth and differentiation, but also increased expression of interleukin 2 receptor on activated B-cells.
  Harada N, Matsumoto M, Koyama N, Shimizu A, Honjo T, Tominaga A, Takatsu K. Harada N, et al. Immunol Lett. 1987 Jul;15(3):205-15. doi: 10.1016/0165-2478(87)90026-5. Immunol Lett. 1987. PMID: 3117678
• T cell-replacing factor in specific antibody responses to influenza virus by human blood B cells.
  Callard RE, Booth RJ, Brown MH, McCaughan GW. Callard RE, et al. Eur J Immunol. 1985 Jan;15(1):52-9. doi: 10.1002/eji.1830150111. Eur J Immunol. 1985. PMID: 2578400
• T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties.
  Takatsu K, Tominaga A, Harada N, Mita S, Matsumoto M, Takahashi T, Kikuchi Y, Yamaguchi N. Takatsu K, et al. Immunol Rev. 1988 Feb;102:107-35. doi: 10.1111/j.1600-065x.1988.tb00743.x. Immunol Rev. 1988. PMID: 3284812 Review.
• Malignant B-cells have receptors for and respond to interleukin-2.
  Panayotides P, Lenkei R, Porwit A, Reizenstein P. Panayotides P, et al. Med Oncol Tumor Pharmacother. 1986;3(3-4):255-63. doi: 10.1007/BF02935002. Med Oncol Tumor Pharmacother. 1986. PMID: 3100885 Review.

Cited by

• Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells.
  Yoshimoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K. Yoshimoto T, et al. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3948-53. doi: 10.1073/pnas.94.8.3948. Proc Natl Acad Sci U S A. 1997. PMID: 9108085 Free PMC article.
• IL-2 enhances polyclonal IgM but not IgM-rheumatoid factor synthesis by activated human peripheral blood B cells.
  Callaghan M, Whelan A, Feighery C, Bresnihan B. Callaghan M, et al. Clin Exp Immunol. 1993 Aug;93(2):212-7. doi: 10.1111/j.1365-2249.1993.tb07968.x. Clin Exp Immunol. 1993. PMID: 8348746 Free PMC article.
• Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.
  Kawamura H, Rosenberg SA, Berzofsky JA. Kawamura H, et al. J Exp Med. 1985 Jul 1;162(1):381-6. doi: 10.1084/jem.162.1.381. J Exp Med. 1985. PMID: 3925070 Free PMC article.
• Single cell studies on the role of B-cell stimulatory factor 1 in B-cell activation.
  Alderson MR, Pike BL, Nossal GJ. Alderson MR, et al. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1389-93. doi: 10.1073/pnas.84.5.1389. Proc Natl Acad Sci U S A. 1987. PMID: 3493492 Free PMC article.
• Administration of recombinant interleukin 2 in vivo induces a polyclonal IgM response.
  Weyand CM, Goronzy J, Dallman MJ, Fathman CG. Weyand CM, et al. J Exp Med. 1986 Jun 1;163(6):1607-12. doi: 10.1084/jem.163.6.1607. J Exp Med. 1986. PMID: 3486940 Free PMC article.

References

1. 1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
2. 1. J Exp Med. 1978 Mar 1;147(3):814-29 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2844-8 - PubMed
4. 1. J Exp Med. 1979 Dec 1;150(6):1510-9 - PubMed
5. 1. Cell. 1980 Jun;20(2):303-12 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations